Press release from Companies

Published: 2023-03-17 11:56:39

WntResearch AB: CEO Pernilla Sandwall invited to present Foxy-5 at scientific workshop on Wnt signalling in Heidelberg on 17 March

Six researchers and two pharmaceutical company representatives active in Wnt signalling will be speakers, including Pernilla Sandwall.

Wnt is the name of a large family of signalling proteins that control and effect a large number of processes in the cell. Unlike hormones and several growth factors, Wnt proteins act primarily in the cell's immediate vicinity through local signalling between adjacent cells. Wnt signals are active in many different contexts, both during early development and in the regulation of normal tissue functions. Of particular interest at this workshop is that several diseases, including cancer, are characterised by altered Wnt signalling.

The workshop is organised by the Collaborative Research Center 1324, a DFG*-funded interdisciplinary research consortium of about 60 researchers focusing on the mechanisms and functions of Wnt signalling. Researchers from the University of Heidelberg work closely with scientists from the medical faculties of Heidelberg and Mannheim as well as from the German Cancer Research Centre (DKFZ), the European Molecular Biology Laboratory (EMBL), the Karlsruhe Institute of Technology (KIT) and the University of Göttingen. *Deutsche Forschungsgemeinschaft (The German Research Foundation)

"I’m honoured to be invited to participate as one of the speakers at this full-day workshop. I will talk about our drug candidate Foxy-5 and about our observations in particular in the ongoing phase 2 study, which I think will be of great interest. WntResearch scientific founder Professor Tommy Andersson will participate via a web link. The title of my presentation is: "Foxy-5, a novel WNT5A mimicking peptide preventing the metastatic process, in clinical development for colon cancer", says Pernilla Sandwall.

For further information:

Pernilla Sandwall, CEO


About Wntresearch AB

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. WntResearch is listed on the Spotlight Stock Market. For more information, please visit: Follow WntResearch on Linked in

Läs mer hos Cision
Read more about WntResearch AB